Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
Program data pending ClinicalTrials.gov matching
· Last scored 2026-03-15
69.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (1)
Quick Facts: Ajinomoto Bio-Pharma Services
- Signal Score
- 69.0/100 (as of 2026-03-15)
- Quality Compliance
- Assessment pending
- Headquarters
- San Diego, CA · Osaka, JP
- Modalities
- Oligonucleotide, Biologics, AAV
- Active CGT Programs
- No ClinicalTrials.gov matches confirmed — 1 partnership announcement in press
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CGT manufacturing intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 1 partnership announcement found in press monitoring.
Programs
— no verified data
Sponsors— no verified data
ModalitiesOligonucleotide, Biologics, AAV
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Partnership Announcements (from press monitoring)
Financial Stability
75.0
Strong parent backing: Ajinomoto Co. (2802.T)
Source: SEC EDGAR, press monitoring
Subsidiary of Ajinomoto Co.
SEC FilingsParent: Ajinomoto Co.
Strong parent backing: Ajinomoto Co. (2802.T)
Capacity
63.0
2 CGT manufacturing sites
Sites: San Diego, CA, Osaka, Japan
Source: SEC EDGAR, press monitoring, company profiles
2 CGT manufacturing sites
Recent Press1 articles
2 CGT manufacturing sites
Recent News 1 articles
The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria - BioSpace
The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria BioSpace
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: